FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4207065622> ?p ?o ?g. }

• W4207065622 endingPage "i548" @default.
• W4207065622 startingPage "i548" @default.
• W4207065622 abstract "Abstract Background Anti-TNFs antibodies are the first biologic treatment option in inflammatory bowel disease (IBD). The long-term effectiveness of this strategy at the population level is poorly known, particularly in pediatric-onset IBD. Methods All patients diagnosed with Crohn’s disease (CD) or ulcerative colitis (UC) before the age of 17 between 1988 and 2011 in a population-based registry were followed retrospectively until 2013. Among patients treated with anti-TNFs, the cumulative probabilities of anti-TNF failure defined by primary failure, loss of response or intolerance were evaluated. Factors associated with anti-TNF failure were investigated by a Cox model. Results Among a total of 1007 patients with CD (median disease duration, 3.2 years IQR (1.2–7.6) and median follow-up 8.8 years (IQR, 4.6–14.2)) and 337 patients with UC (median disease duration, 2.5 years IQR [1.1–4.5] and median follow-up 7.2 years (IQR, 3.8–13.0)), respectively 481 (48%) and 81 (24%) were treated with anti-TNFs. Median age at anti-TNF initiation was 17.4 years (IQR, 15.1–20.9). Median duration of anti-TNF therapy was 20.4 months (IQR, 6.0–59.9). In CD, the probability of failure of 1st line anti-TNF therapy at 1, 3 and 5 years was respectively 29.3%, 47.0% and 54.6% for infliximab (n = 397) and 22.6%, 37.7% and 48.0% for adalimumab (n = 83). In UC, the probability of failure of 1st line anti-TNF therapy at 1, 3 and 5 years was respectively 37.3%, 49.0% and 61.0% for infliximab (n = 71) and 12.5% for these 3 timepoints for adalimumab (n = 10). In CD, probabilities of primary failure, loss of response and intolerance at 5 years were 10.4%, 36.7% and 6.8% (n = 480), respectively; in UC, these same probabilities were 7.5%, 39.2% and 11.3% (n = 81), respectively. Female sex (Hazard Ratio (HR) 1.43, 95% CI 1.09–1.87; p = 0.010) and intestinal resection prior anti-TNF initiation (HR 1.73, 95% CI 1.21–2.47, p = 0.003) were associated with anti-TNF failure in multivariate analysis. Conclusion In a population-based study of pediatric-onset IBD, approximately half of anti-TNFs users discontinue use within 5 years. Loss of response account for around two-thirds of failure, both for CD and UC." @default.
• W4207065622 created "2022-01-26" @default.
• W4207065622 creator A5017744765 @default.
• W4207065622 creator A5028944882 @default.
• W4207065622 creator A5043979820 @default.
• W4207065622 creator A5047976667 @default.
• W4207065622 creator A5056614296 @default.
• W4207065622 creator A5060697354 @default.
• W4207065622 creator A5061397027 @default.
• W4207065622 creator A5065655219 @default.
• W4207065622 creator A5068268866 @default.
• W4207065622 creator A5073322732 @default.
• W4207065622 creator A5082560779 @default.
• W4207065622 creator A5087047716 @default.
• W4207065622 date "2022-01-01" @default.
• W4207065622 modified "2023-09-27" @default.
• W4207065622 title "P624 Long-term effectiveness of anti-TNF therapy in pediatric-onset inflammatory bowel diseases: a population-based study" @default.
• W4207065622 doi "https://doi.org/10.1093/ecco-jcc/jjab232.750" @default.
• W4207065622 hasPublicationYear "2022" @default.
• W4207065622 type Work @default.
• W4207065622 citedByCount "0" @default.
• W4207065622 crossrefType "journal-article" @default.
• W4207065622 hasAuthorship W4207065622A5017744765 @default.
• W4207065622 hasAuthorship W4207065622A5028944882 @default.
• W4207065622 hasAuthorship W4207065622A5043979820 @default.
• W4207065622 hasAuthorship W4207065622A5047976667 @default.
• W4207065622 hasAuthorship W4207065622A5056614296 @default.
• W4207065622 hasAuthorship W4207065622A5060697354 @default.
• W4207065622 hasAuthorship W4207065622A5061397027 @default.
• W4207065622 hasAuthorship W4207065622A5065655219 @default.
• W4207065622 hasAuthorship W4207065622A5068268866 @default.
• W4207065622 hasAuthorship W4207065622A5073322732 @default.
• W4207065622 hasAuthorship W4207065622A5082560779 @default.
• W4207065622 hasAuthorship W4207065622A5087047716 @default.
• W4207065622 hasBestOaLocation W42070656221 @default.
• W4207065622 hasConcept C126322002 @default.
• W4207065622 hasConcept C141071460 @default.
• W4207065622 hasConcept C2777138892 @default.
• W4207065622 hasConcept C2778260677 @default.
• W4207065622 hasConcept C2779134260 @default.
• W4207065622 hasConcept C2779280984 @default.
• W4207065622 hasConcept C2780132546 @default.
• W4207065622 hasConcept C2780479503 @default.
• W4207065622 hasConcept C2908647359 @default.
• W4207065622 hasConcept C71924100 @default.
• W4207065622 hasConcept C90924648 @default.
• W4207065622 hasConcept C99454951 @default.
• W4207065622 hasConceptScore W4207065622C126322002 @default.
• W4207065622 hasConceptScore W4207065622C141071460 @default.
• W4207065622 hasConceptScore W4207065622C2777138892 @default.
• W4207065622 hasConceptScore W4207065622C2778260677 @default.
• W4207065622 hasConceptScore W4207065622C2779134260 @default.
• W4207065622 hasConceptScore W4207065622C2779280984 @default.
• W4207065622 hasConceptScore W4207065622C2780132546 @default.
• W4207065622 hasConceptScore W4207065622C2780479503 @default.
• W4207065622 hasConceptScore W4207065622C2908647359 @default.
• W4207065622 hasConceptScore W4207065622C71924100 @default.
• W4207065622 hasConceptScore W4207065622C90924648 @default.
• W4207065622 hasConceptScore W4207065622C99454951 @default.
• W4207065622 hasIssue "Supplement_1" @default.
• W4207065622 hasLocation W42070656221 @default.
• W4207065622 hasOpenAccess W4207065622 @default.
• W4207065622 hasPrimaryLocation W42070656221 @default.
• W4207065622 hasRelatedWork W1708680437 @default.
• W4207065622 hasRelatedWork W1968760412 @default.
• W4207065622 hasRelatedWork W2296926020 @default.
• W4207065622 hasRelatedWork W2321888678 @default.
• W4207065622 hasRelatedWork W2419464638 @default.
• W4207065622 hasRelatedWork W2617260208 @default.
• W4207065622 hasRelatedWork W2945945073 @default.
• W4207065622 hasRelatedWork W3022383156 @default.
• W4207065622 hasRelatedWork W3123012725 @default.
• W4207065622 hasRelatedWork W4243474418 @default.
• W4207065622 hasVolume "16" @default.
• W4207065622 isParatext "false" @default.
• W4207065622 isRetracted "false" @default.
• W4207065622 workType "article" @default.